Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary
暂无分享,去创建一个
Peter Lindgren | Ilse Vanhorebeek | Silvia G Priori | Bengt Jönsson | Marco Stramba-Badiale | John Camm | Eberhard Standl | John Betteridge | Erland Erdmann | Michel Bertrand | Qing Qiao | Jaakko Tuomilehto | Massimo Volpe | Lars Rydén | M. Laakso | G. Van den Berghe | J. Camm | K. Dickstein | S. Priori | G. V. Berghe | J. Tuomilehto | L. Rydén | J. Tamargo | J. Blanc | A. Budaj | Verónica Dean | J. Deckers | J. Lekakis | K. Mcgregor | M. Metra | J. Morais | A. Osterspey | J. Zamorano | K. Pyörälä | K. Malmberg | E. Erdmann | E. Ferrannini | M. Bertrand | M. Volpe | B. Jönsson | M. de Boer | D. Wood | I. Vanhorebeek | B. Charbonnel | A. Flyvbjerg | I. Raz | G. Schernthaner | K. Parhofer | E. Standl | F. Cosentino | M. Stramba-Badiale | Q. Qiao | H. Gohlke | J. Betteridge | J. Ostergren | Jan Ostergren | Greet Van den Berghe | John Lekakis | Jaap W Deckers | Ele Ferrannini | Jean-Jacques Blanc | João Morais | Andrzej Budaj | Jaap Deckers | Keith McGregor | Markku Laakso | Itamar Raz | José Luis Zamorano | Allan Flyvbjerg | Juan Tamargo | Menko-Jan de Boer | Guntram Schernthaner | Kalevi Pyörälä | David Wood | Veronica Dean | Kenneth Dickstein | Francesco Cosentino | Małgorzata Bartnik | Klas Malmberg | Marco Metra | Ady Osterspey | I. Thrainsdottir | Klaus Parhofer | Helmut Gohlke | Inga Thrainsdottir | Bernard Charbonnel | Jose Ramon Gonzalez Juanatey | Pedro Filipe Monteiro | Silvia Priori | P. Lindgren | M. Bartnik | J. R. Juanatey | I. Graham | P. Monteiro | Ian Graham | K. Pyörälä | J. Juanatey | V. Dean
[1] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .
[2] M. Shipley,et al. CORONARY-HEART-DISEASE RISK AND IMPAIRED GLUCOSE TOLERANCE The Whitehall Study , 1980, The Lancet.
[3] R. Rutherford,et al. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). , 2000, Journal of vascular surgery.
[4] Erzo F. P. Luttmer,et al. The Cost of Diabetes , 1989, Diabetic medicine : a journal of the British Diabetic Association.
[5] J. Deckers,et al. Efficacy of long-term anticoagulant treatment in subgroups of patients after myocardial infarction. , 1995, British heart journal.
[6] J. Halperin,et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). , 1999, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[7] M. Schroll,et al. Stroke incidence, case fatality, and mortality in the WHO MONICA project. World Health Organization Monitoring Trends and Determinants in Cardiovascular Disease. , 1995, Stroke.
[8] Claude Lenfant,et al. Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Circulation.
[9] L. Groop,et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.
[10] G. Remuzzi,et al. Preventing microalbuminuria in type 2 diabetes. , 2004, The New England journal of medicine.
[11] Joël Ménard,et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.
[12] O. Schnell,et al. Hospital outcome of acute myocardial infarction in patients with and without diabetes mellitus , 2004, Diabetic medicine : a journal of the British Diabetic Association.
[13] D N Mendelson,et al. Health care expenditures for people with diabetes mellitus, 1992. , 1994, The Journal of clinical endocrinology and metabolism.
[14] A. Marette,et al. Regulation of expression of glucose transporters by glucose: a review of studies in vivo and in cell cultures , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[15] M. Harris,et al. Diabetes and decline in heart disease mortality in US adults. , 1999, JAMA.
[16] E. Feskens,et al. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria , 1999, The Lancet.
[17] J. Gore,et al. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. , 2004, Archives of internal medicine.
[18] Zygimantas Cepaitis,et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. , 2005, Diabetes.
[19] M. Bartnik. Glucose regulation and coronary artery disease : Studies on prevalence, recognition and prognostic implications , 2005 .
[20] D. Barbier. [Depression in the elderly. Clinical aspects]. , 2001, Presse medicale.
[21] M. Chaney,et al. Attempting to maintain normoglycemia during cardiopulmonary bypass with insulin may initiate postoperative hypoglycemia. , 1999, Anesthesia and analgesia.
[22] E. Ford. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. , 2004, Atherosclerosis.
[23] W. C. Sheldon,et al. Reconstructive Coronary Artery Surgery: Postoperative Assessment , 1969, Circulation.
[24] R. Detrano,et al. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. , 2004, JAMA.
[25] Philip D. Harvey,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.
[26] M. Apkon,et al. Persistent hyperglycemia in critically ill children. , 2005, The Journal of pediatrics.
[27] J. Shaw,et al. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality , 1999, Diabetologia.
[28] F. Tediosi,et al. Costs of diabetes. A methodological analysis of the literature. , 1999, PharmacoEconomics.
[29] P. Bennett,et al. Follow-up of the WHO multinational study of vascular disease in diabetes: general description and morbidity , 2001, Diabetologia.
[30] B. Mitchell,et al. Screening for silent coronary heart disease in type 2 diabetes: clinical application of American Diabetes Association guidelines. , 2006, Diabetes care.
[31] James W. Anderson,et al. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may Be due to the abnormal composition of HDL. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[32] L. Bouter,et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. , 2005, Diabetes care.
[33] T. Valle,et al. Occupational, commuting, and leisure-time physical activity in relation to risk for Type 2 diabetes in middle-aged Finnish men and women , 2003, Diabetologia.
[34] R. Califf,et al. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Aypass Angioplasty Revascularization Investigation (BARI). , 1999, Circulation.
[35] S M Nazarian,et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. , 1992, The New England journal of medicine.
[36] Arno W. Hoes,et al. Peripheral arterial disease in the elderly: The Rotterdam Study. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[37] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[38] R. Wolfe,et al. TNF directly stimulates glucose uptake and leucine oxidation and inhibits FFA flux in conscious dogs. , 1996, The American journal of physiology.
[39] Jagmeet P. Singh,et al. Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). , 2000, The American journal of cardiology.
[40] A Hofman,et al. Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. , 1999, European heart journal.
[41] J. P. O’Hare,et al. The prevalence of autonomic neuropathy in insulin-dependent diabetes mellitus: a controlled study based on heart rate variability. , 1986, The Quarterly journal of medicine.
[42] Terje R Pedersen,et al. Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.
[43] G. Specchia,et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2002, European heart journal.
[44] N. Clark,et al. Standards of Medical Care in Diabetes: Response to Power , 2006 .
[45] A. Hamsten,et al. Insulin, intact and split proinsulin, and coronary artery disease in young men. , 1995, Circulation.
[46] G. L’italien,et al. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. , 2003, The American journal of cardiology.
[47] P. Wolf,et al. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.
[48] E. Vittinghoff,et al. Glycemic Effects of Postmenopausal Hormone Therapy: The Heart and Estrogen/progestin Replacement Study: A Randomized, Double-Blind, Placebo-Controlled Trial , 2003, Annals of Internal Medicine.
[49] B. Rutherford,et al. Diabetes mellitus is associated with a shift in the temporal risk profile of inhospital death after percutaneous coronary intervention: an analysis of 25,223 patients over 20 years. , 2003, American heart journal.
[50] Miet Schetz,et al. Strict blood glucose control with insulin during intensive care after cardiac surgery: impact on 4-years survival, dependency on medical care, and quality-of-life. , 2006, European heart journal.
[51] P. Serruys,et al. Comparison of short- (one month) and long- (twelve months) term outcomes of sirolimus- versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries). , 2005, American Journal of Cardiology.
[52] C. Lan,et al. Prevalence of stroke in Taiwan. , 1989, Stroke.
[53] A. Maggioni,et al. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. , 1997, Circulation.
[54] S. Yusuf,et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.
[55] Diederick Grobbee,et al. Randomized Comparison Between Stenting and Off-Pump Bypass Surgery in Patients Referred for Angioplasty , 2003, Circulation.
[56] Richard Kahn,et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. , 2005, Diabetes care.
[57] J. Hsia,et al. Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes , 2006, Diabetes Care.
[58] N. Waugh,et al. Mortality From Cerebrovascular Disease in a Cohort of 23 000 Patients With Insulin-Treated Diabetes , 2003, Stroke.
[59] H. Gerstein,et al. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview , 2000, The Lancet.
[60] H. Tunstall-Pedoe,et al. Myocardial Infarction and Coronary Deaths in the World Health Organization MONICA Project: Registration Procedures, Event Rates, and Case‐Fatality Rates in 38 Populations From 21 Countries in Four Continents , 1994, Circulation.
[61] R. Holman,et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23) , 1998, BMJ.
[62] Beverley Balkau,et al. Age- and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. , 2003, Diabetes care.
[63] Sankey V. Williams,et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). , 2003, Circulation.
[64] M. Simoons,et al. Unstable angina: good long-term outcome after a complicated early course. , 1998, Journal of the American College of Cardiology.
[65] Neil J Grey,et al. Reduction of nosocomial infections in the surgical intensive-care unit by strict glycemic control. , 2004, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[66] C. Snehalatha,et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1) , 2006, Diabetologia.
[67] V. Katch,et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. , 1989, The New England journal of medicine.
[68] L. Rydén,et al. Tissue Doppler imaging for the detection and quantitation of myocardial dysfunction in patients with type 2 diabetes mellitus , 2005, Diabetes & vascular disease research.
[69] Georgeanne Botek,et al. Treatment for diabetic foot ulcers , 2005, The Lancet.
[70] C. Imray,et al. Are some strokes preventable? The potential role of transcranial doppler in transient ischaemic attacks of carotid origin , 2005, The Lancet Neurology.
[71] K. Swedberg,et al. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.
[72] D. Levy,et al. Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.
[73] B. Howard,et al. Lowering fatty acids potentiates acute insulin response in first degree relatives of people with Type II diabetes , 1998, Diabetologia.
[74] Philip J. Barter,et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.
[75] S. Solomon,et al. Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction: The Valsartan in Acute Myocardial Infarction (VALIANT) Trial , 2004, Circulation.
[76] J. Huttunen,et al. Coronary Heart Disease Incidence in NIDDM Patients In The Helsinki Heart Study , 1992, Diabetes Care.
[77] M. Omata,et al. Reduced myocardial flow reserve in non-insulin-dependent diabetes mellitus. , 1997, Journal of the American College of Cardiology.
[78] Farris K. Timimi,et al. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. , 1996, The Journal of clinical investigation.
[79] E. Standl,et al. The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type II diabetes mellitus , 2003, Diabetologia.
[80] G. Tinkoff,et al. Admission hyperglycemia as a prognostic indicator in trauma. , 2003, The Journal of trauma.
[81] J. Sturis,et al. Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. , 1996, The New England journal of medicine.
[82] K. Malmberg,et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. , 2004, Journal of the American College of Cardiology.
[83] A Hofman,et al. The prognosis of heart failure in the general population: The Rotterdam Study. , 2001, European heart journal.
[84] I. Palacios,et al. Drug-eluting stents for diabetes mellitus: a rush to judgment? , 2005, Journal of the American College of Cardiology.
[85] T. Marwick,et al. Effects of glucose–insulin–potassium infusion on chronic ischaemic left ventricular dysfunction , 2003, Heart.
[86] G. Radda,et al. Uncoupling proteins in human heart , 2004, The Lancet.
[87] D. Porte,et al. Glycosylated Hemoglobin and Fasting Plasma Glucose in the Assessment of Outpatient Glycemic Control in NIDDM , 1982, Diabetes Care.
[88] M. Hanefeld,et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up , 1996, Diabetologia.
[89] W. Koenig,et al. The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up study. , 2000, Diabetologia.
[90] Erland Erdmann,et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.
[91] S. Pocock,et al. Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting , 1998, The Lancet.
[92] P. Stacpoole,et al. Effects of dichloroacetate in patients with congestive heart failure , 1998, Clinical cardiology.
[93] D. Betteridge,et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial☆ , 2004 .
[94] Tom Fahey,et al. Predictive accuracy of the Framingham coronary risk score in British men:prospective cohort study , 2003, BMJ : British Medical Journal.
[95] P. Dyck,et al. Sudden cardiac death in diabetes mellitus: risk factors in the Rochester diabetic neuropathy study , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[96] R. Loewenson,et al. Influence of Pancreas Transplantation on Cardiorespiratory Reflexes, Nerve Conduction, and Mortality in Diabetes Mellitus , 1990, Diabetes.
[97] J. Killian,et al. Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. , 2002, Journal of the American College of Cardiology.
[98] F. Lobo,et al. Direct health care costs of diabetic patients in Spain. , 2004, Diabetes care.
[99] M L Simoons,et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). , 2002, European heart journal.
[100] R. D'Agostino,et al. Risk of Hospitalized Stroke in Men Enrolled in the Honolulu Heart Program and the Framingham Study: A Comparison of Incidence and Risk Factor Effects , 2002, Stroke.
[101] Masafumi Matsuda,et al. beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. , 2005, The Journal of clinical endocrinology and metabolism.
[102] D. Singer,et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.
[103] A. Hamsten,et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study , 2002, The Lancet.
[104] Darren K Mcguire,et al. Influence of diabetes on long‐term outcome among unselected patients with acute coronary events , 2004, Scandinavian cardiovascular journal : SCJ.
[105] R. Campbell,et al. Management Strategies for a Better Outcome in Unstable Coronary Artery Disease , 1998, Clinical cardiology.
[106] W. Weintraub,et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. , 1995, Circulation.
[107] M. Mclean,et al. The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. , 2006, Diabetes care.
[108] Roberto Ferrari,et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. , 2004, European heart journal.
[109] B. Jönsson. Diabetes--the cost of illness and the cost of control. An estimate for Sweden 1978. , 1983, Acta medica Scandinavica. Supplementum.
[110] A. Hofman,et al. Prevalence and Risk Factors of Silent Brain Infarcts in the Population-Based Rotterdam Scan Study , 2002, Stroke.
[111] Bertram Pitt,et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.
[112] N. Christensen,et al. Hemodynamics in diabetic orthostatic hypotension. , 1981, The Journal of clinical investigation.
[113] M. Fowler. Clinical Practice Recommendations , 2009, Clinical Diabetes.
[114] M. Laakso,et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial , 2006, The Lancet.
[115] D. Kereiakes,et al. Metabolic syndrome epidemic. , 2003, Circulation.
[116] Catherine Kim,et al. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. , 2002, Diabetes care.
[117] J. W. Box,et al. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb Study , 2000 .
[118] Johan Herlitz,et al. Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .
[119] V. Gudnason,et al. Glucose abnormalities and heart failure predict poor prognosis in the population-based Reykjavik Study , 2005, European Journal of Cardiovascular Prevention & Rehabilitation.
[120] M. Rewers,et al. Global Estimates for Prevalence of Diabetes Mellitus and Impaired Glucose Tolerance in Adults , 1993, Diabetes Care.
[121] A. K. Jonassen,et al. Glucose-Insulin-Potassium Reduces Infarct Size When Administered During Reperfusion , 2000, Cardiovascular Drugs and Therapy.
[122] M. Laakso,et al. Proteinuria and metabolic syndrome as predictors of cardiovascular death in non-diabetic and type 2 diabetic men and women , 2005, Diabetologia.
[123] J. Stamler,et al. Asymptomatic hyperglycemia and coronary heart disease. A series of papers by the International Collaborative Group, based on studies in fifteen populations. Introduction. , 1979, Journal of chronic diseases.
[124] G. Fonarow,et al. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. , 2005, American heart journal.
[125] N. Ray,et al. Economic Consequences of Diabetes Mellitus in the U.S. in 1997 , 1998, Diabetes Care.
[126] B. Howard,et al. Diabetes and cardiovascular disease , 2000, Annual review of medicine.
[127] J. Hokanson,et al. Dyslipidemia of central obesity and insulin resistance. , 1999, Diabetes Care.
[128] S. Grundy. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. , 1999, The American journal of cardiology.
[129] B. Lüderitz,et al. Atrial fibrillation: relation between clinical risk factors and transoesophageal echocardiographic risk factors for thromboembolism , 2003, Heart.
[130] M. Pirisi,et al. Hyperglycemia-Induced Thrombin Formation in Diabetes: The Possible Role of Oxidative Stress , 1995, Diabetes.
[131] Bendix Carstensen,et al. A Danish diabetes risk score for targeted screening: the Inter99 study. , 2004, Diabetes care.
[132] P. Serruys,et al. Clinical and Economic Impact of Diabetes Mellitus on Percutaneous and Surgical Treatment of Multivessel Coronary Disease Patients: Insights From the Arterial Revascularization Therapy Study (ARTS) Trial , 2001, Circulation.
[133] Carmen Castaneda-Sceppa,et al. Physical activity/exercise and type 2 diabetes. , 2004, Diabetes care.
[134] G. Stone,et al. Short- and long-term results after multivessel stenting in diabetic patients. , 2004, Journal of the American College of Cardiology.
[135] P. Whelton,et al. Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) , 2005 .
[136] P. Whelton,et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. , 2001, Archives of internal medicine.
[137] M. Hanefeld,et al. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. , 2000, Diabetes care.
[138] E. Falk,et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. , 2003, European heart journal.
[139] J. Hopper,et al. Stroke topography and outcome in relation to hyperglycaemia and diabetes. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[140] D. Moliterno,et al. Diabetes and percutaneous coronary intervention: the sweet smell of success? , 2003, American heart journal.
[141] S. Shinnar,et al. The trials and tribulations of pediatric drug trials , 2005, Neurology.
[142] M. Borger,et al. Prevention and management of deep sternal wound infection. , 2004, Seminars in thoracic and cardiovascular surgery.
[143] Mckendry Jb. Direct costs of diabetes care: a survey in Ottawa, Ontario 1986. , 1989 .
[144] S. Neugebauer,et al. Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention. , 1997, Drugs.
[145] B. Jönsson,et al. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial , 1999, Diabetologia.
[146] S. Yusuf,et al. Effects of the Angiotensin Converting Enzyme Inhibitor Enalapril on the Long‐term: Progression of Left Ventricular Dysfunction in Patients With Heart Failure , 1992, Circulation.
[147] Daniel L. McGee,et al. Diabetes and cardiovascular disease. The Framingham study. , 1979, JAMA.
[148] M. Muggeo,et al. Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Group. , 1996, Diabetes care.
[149] Greet Van den Berghe,et al. How does blood glucose control with insulin save lives in intensive care , 2004 .
[150] W. Rathmann,et al. Prevalence and clinical correlates of cardiovascular autonomic and peripheral diabetic neuropathy in patients attending diabetes centers. The Diacan Multicenter Study Group. , 1993, Diabete & metabolisme.
[151] A. Connor,et al. The way I see it: House officers need formal career development , 2002 .
[152] J. Pomposelli,et al. Effect of interleukin-1 and tumor necrosis factor/cachectin on glucose turnover in the rat. , 1990, Metabolism: clinical and experimental.
[153] D. DeMets,et al. Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.
[154] A. Malhotra,et al. Stress-induced hyperglycemia. , 2001, Critical care clinics.
[155] T. Nhlapo. Women and the constitution: what to do when culture strikes back. , 1992, Southern Africa political & economic monthly.
[156] SamuelLévy,et al. Characterization of Different Subsets of Atrial Fibrillation in General Practice in France , 1999 .
[157] CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.
[158] E. Bonora,et al. The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study , 2004, Diabetic medicine : a journal of the British Diabetic Association.
[159] T. Münzel,et al. Mechanisms Underlying Endothelial Dysfunction in Diabetes Mellitus , 2001, Circulation research.
[160] Kathryn Tan,et al. Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966–2004)* , 2005, Current medical research and opinion.
[161] K. Borch-Johnsen,et al. Hypertension in people with Type 2 diabetes: knowledge‐based diabetes‐specific guidelines , 2003, Diabetic medicine : a journal of the British Diabetic Association.
[162] S. Haffner,et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. , 2002, Diabetes.
[163] Neil J Stone,et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.
[164] G. Keresztury,et al. Atherosclerosis in amputated legs of patients with and without diabetes mellitus. , 1998, International angiology : a journal of the International Union of Angiology.
[165] S. Yusuf,et al. Effect of ramipril on the incidence of diabetes. , 2006, The New England journal of medicine.
[166] O'Neill Ww. Multivessel balloon angioplasty should be abandoned in diabetic patients , 1998 .
[167] T. Lüscher,et al. Atherosclerosis and the two faces of endothelial nitric oxide synthase. , 1998, Circulation.
[168] G. Shulman,et al. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β‐cell dysfunction , 2002, European journal of clinical investigation.
[169] S. Marso. Optimizing the diabetic formulary: beyond aspirin and insulin. , 2002, Journal of the American College of Cardiology.
[170] A. Hoes,et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.
[171] D. Giugliano,et al. Evidence for a hyperglycaemia-dependent decrease of antithrombin III-thrombin complex formation in humans , 1990, Diabetologia.
[172] A. Kriska,et al. Handbook of Exercise in Diabetes , 2004 .
[173] R. Holman,et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.
[174] A. Dyer,et al. Diabetes, Asymptomatic Hyperglycemia, and 22-Year Mortality in Black and White Men: The Chicago Heart Association Detection Project in Industry Study , 1997, Diabetes Care.
[175] R F Anda,et al. Impact of multiple risk factor profiles on determining cardiovascular disease risk. , 1998, Preventive medicine.
[176] E. Barrett-Connor,et al. Diabetes mellitus: an independent risk factor for stroke? , 1988, American journal of epidemiology.
[177] F A Mathewson,et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. , 1995, The American journal of medicine.
[178] G. Rozanski,et al. A Metabolic Mechanism For Cardiac K+ Channel Remodelling , 2002, Clinical and experimental pharmacology & physiology.
[179] K. Narayan,et al. Preventing Non-Insulin-Dependent Diabetes , 1995, Diabetes.
[180] E Geraci,et al. Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart. , 2001, European heart journal.
[181] J. Simoneau,et al. Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus. , 1994, The Journal of clinical investigation.
[182] Walter C Willett,et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. , 2002, Diabetes care.
[183] J. Tuomilehto,et al. Predictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow-up. , 2003, Diabetes care.
[184] S. Yusuf,et al. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. , 1999, Diabetes care.
[185] R. Holle,et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project , 1996, Diabetologia.
[186] C. Bauters,et al. Patency of Percutaneous Transluminal Coronary Angioplasty Sites at 6-Month Angiographic Follow-Up: A Key Determinant of Survival in Diabetics After Coronary Balloon Angioplasty , 2001, Circulation.
[187] R. Holman,et al. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72) , 2005, Diabetologia.
[188] A. Vinik. Diagnosis and management of diabetic neuropathy. , 1999, Clinics in geriatric medicine.
[189] U Ravens,et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. , 2001, European heart journal.
[190] B. Gersh,et al. Methods of coronary revascularization--things may not be as they seem. , 2005, The New England journal of medicine.
[191] C. Cogbill,et al. Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform? , 2003, Journal of the American College of Cardiology.
[192] R. Collins,et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri , 2005, The Lancet.
[193] L. Sjöström,et al. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. , 1983, The Journal of clinical investigation.
[194] A. Jacobs,et al. Comparison of in-hospital and one-year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). , 2002, The American journal of cardiology.
[195] T. Kuzuya,et al. Classification of Diabetes on the Basis of Etiologies Versus Degree of Insulin Deficiency , 1997, Diabetes Care.
[196] D. Mikhailidis,et al. Early Benefit from Structured Care with Atorvastatin in Patients with Coronary Heart Disease and Diabetes Mellitus , 2003, Angiology.
[197] Z. Bloomgarden. American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC. , 2003, Diabetes care.
[198] A. Kissebah,et al. Relation of Body Fat Distribution to Metabolic Complications of Obesity , 1982 .
[199] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[200] B. Horne,et al. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. , 2003, American heart journal.
[201] G. Deichsel,et al. DRUG-INDUCED INHIBITION OF PLATELET FUNCTION DELAYS PROGRESSION OF PERIPHERAL OCCLUSIVE ARTERIAL DISEASE A Prospective Double-Blind Arteriographically Controlled Trial , 1985, The Lancet.
[202] Steven Hawken,et al. Preventive cardiologyAbstractsEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study , 2004 .
[203] G. Leese,et al. The Management of Hypertension in Diabetes: with Special Reference to Diabetic Kidney Disease , 1996, Diabetic medicine : a journal of the British Diabetic Association.
[204] S. Yusuf,et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[205] R. Herings,et al. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme , 1995, The Lancet.
[206] Matthijs Oudkerk,et al. Incidence and Risk Factors of Silent Brain Infarcts in the Population-Based Rotterdam Scan Study , 2003, Stroke.
[207] Chalmers Tc,et al. A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. , 1994, International angiology : a journal of the International Union of Angiology.
[208] S. Anker,et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. , 1997, Journal of the American College of Cardiology.
[209] James Stephen Krinsley,et al. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. , 2004, Mayo Clinic proceedings.
[210] C. Bauters,et al. Restenosis, late vessel occlusion and left ventricular function six months after balloon angioplasty in diabetic patients. , 1999, Journal of the American College of Cardiology.
[211] L. Landsberg. Insulin resistance and the metabolic syndrome , 2005, Diabetologia.
[212] J Wayne Meredith,et al. Relationship of early hyperglycemia to mortality in trauma patients. , 2004, The Journal of trauma.
[213] C. Furberg,et al. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. , 1989, BMJ.
[214] L. Elveback,et al. Transient ischemic attack and stroke in a community-based diabetic cohort. , 1983, Mayo Clinic proceedings.
[215] C H Lang,et al. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. , 1992, Endocrinology.
[216] Palle Petersen,et al. PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION The Copenhagen AFASAK Study , 1989, The Lancet.
[217] C. Gullion,et al. The incidence of congestive heart failure in type 2 diabetes: an update. , 2004, Diabetes care.
[218] L. Rydén,et al. Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes: a report from the GAMI study , 2005, Diabetologia.
[219] T. Songer. The economic costs of NIDDM. , 1992, Diabetes/metabolism reviews.
[220] B. Zinman,et al. Physical activity/exercise and diabetes mellitus. , 2003, Diabetes care.
[221] C. Palmer,et al. Outcomes With Nifedipine GITS or Co-Amilozide in Hypertensive Diabetics and Nondiabetics in Intervention as a Goal in Hypertension (INSIGHT) , 2003, Hypertension.
[222] K. Dickstein,et al. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial , 2002, The Lancet.
[223] U. Goldbourt,et al. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group. , 1996, The American journal of cardiology.
[224] Karl Swedberg,et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.
[225] J. Ottervanger,et al. Treatment decisions in stable coronary artery disease: insights from the Euro Heart Survey on Coronary Revascularization. , 2006, The Journal of thoracic and cardiovascular surgery.
[226] G. Albers,et al. Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. , 2004, Journal of the American College of Cardiology.
[227] J. Manson,et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.
[228] W. C. Sheldon,et al. Reconstructive coronary artery surgery. Venous autograft technique. , 1970, JAMA.
[229] A. Hedley,et al. A prospective population based study of gender differential in mortality from cardiovascular disease and "all causes" in asymptomatic hyperglycaemics. , 1994, Journal of clinical epidemiology.
[230] Philip P Goodney,et al. Current status of carotid artery stenting. , 2006, Journal of vascular surgery.
[231] P. Wolf,et al. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. , 1987, Archives of internal medicine.
[232] Helmut Schulte,et al. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany--results from the MONICA Augsburg and the PROCAM cohorts. , 2003, European heart journal.
[233] J. Tuomilehto,et al. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. , 2000, Diabetes care.
[234] M. Blombäck,et al. Effect of dalteparin on healing of chronic foot ulcers in diabetic patients with peripheral arterial occlusive disease: a prospective, randomized, double-blind, placebo-controlled study. , 2003, Diabetes care.
[235] James T. Willerson,et al. Appointment of New Associate Editor for Circulation , 1996 .
[236] D. Dhanwal,et al. Silent myocardial ischaemia in patients with type II diabetes mellitus and its relation with autonomic dysfunction. , 2000, Indian heart journal.
[237] M. Mack,et al. Influence of diabetes on mortality and morbidity: off-pump coronary artery bypass grafting versus coronary artery bypass grafting with cardiopulmonary bypass. , 2001, The Annals of thoracic surgery.
[238] S. Haffner,et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). , 2000, Circulation.
[239] P. Poole‐Wilson,et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. , 2000, European heart journal.
[240] L. Wilhelmsen,et al. Heart failure in the general population of men--morbidity, risk factors and prognosis. , 2001, Journal of internal medicine.
[241] S. Saydah,et al. Postchallenge hyperglycemia and mortality in a national sample of U.S. adults. , 2001, Diabetes care.
[242] J. Muller,et al. Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. , 2001, Diabetes care.
[243] K. Eriksson,et al. Prevention of Type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise The 6-year Malmö feasibility study , 1991, Diabetologia.
[244] Patrick W Serruys,et al. The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase. , 2006, American heart journal.
[245] P. Herrero,et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. , 2002, Journal of the American College of Cardiology.
[246] M. Laakso,et al. European Stroke Prevention Study: Effectiveness of Antiplatelet Therapy in Diabetic Patients in Secondary Prevention of Stroke , 1992, Stroke.
[247] D. Lawlor,et al. Does the new International Diabetes Federation definition of the metabolic syndrome predict CHD any more strongly than older definitions? Findings from the British Women’s Heart and Health Study , 2005, Diabetologia.
[248] T. Jørgensen,et al. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. , 2002, International journal of epidemiology.
[249] S. Haffner,et al. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome , 1991, Diabetologia.
[250] JoAnn E. Manson,et al. Prospective Study of Sudden Cardiac Death Among Women in the United States , 2003, Circulation.
[251] T. Lüscher,et al. High Glucose Causes Upregulation of Cyclooxygenase-2 and Alters Prostanoid Profile in Human Endothelial Cells: Role of Protein Kinase C and Reactive Oxygen Species , 2003, Circulation.
[252] M. Cybulsky,et al. Advanced Glycation Endproducts Promote Adhesion Molecule (VCAM-1, ICAM-1) Expression and Atheroma Formation in Normal Rabbits , 1995, Molecular medicine.
[253] P. Poole‐Wilson,et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol european trial (COMET): randomized controlled trial☆ , 2003 .
[254] G. Sundkvist,et al. A 14‐year prospective study of autonomic nerve function in Type 1 diabetic patients: association with nephropathy , 2004, Diabetic medicine : a journal of the British Diabetic Association.
[255] W. Tamborlane,et al. The normal glucose tolerance continuum in obese youth: evidence for impairment in beta-cell function independent of insulin resistance. , 2005, The Journal of clinical endocrinology and metabolism.
[256] A. Pfeiffer,et al. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro , 2001, Diabetologia.
[257] M. Laakso,et al. Age of Onset and Type of Diabetes , 1985, Diabetes Care.
[258] A. Shehadeh,et al. Cardiac consequences of diabetes mellitus , 1995, Clinical cardiology.
[259] E. Barrett-Connor,et al. Sex differences in fasting glycemia as a risk factor for ischemic heart disease death. , 1991, American journal of epidemiology.
[260] A Sekikawa,et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. , 1999, Diabetes care.
[261] Martha J. Radford,et al. Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .
[262] L. Rydén,et al. Abnormal glucose tolerance – a common risk factor in patients with acute myocardial infarction in comparison with population‐based controls , 2004, Journal of internal medicine.
[263] E. Gale. The myth of the metabolic syndrome , 2005, Diabetologia.
[264] S. Yusuf,et al. Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes. , 2005, Canadian journal of physiology and pharmacology.
[265] K. Dickstein,et al. Effects of losartan and captopril on mortality and morbidity after acute myocardial infarction: The OPTIMAAL randomized trial. , 2002 .
[266] K. Yano,et al. Sudden death, impaired glucose tolerance, and diabetes in Japanese American men. , 1995, Circulation.
[267] S. Grundy,et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[268] M. Wallander,et al. Incidence of newly diagnosed heart failure in UK general practice , 2001, European journal of heart failure.
[269] C. Östenson,et al. Direct medical costs for patients with type 2 diabetes in Sweden , 2000, Journal of internal medicine.
[270] L. Monti,et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. , 2003, American heart journal.
[271] E. Standl,et al. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. , 2000, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[272] Steven Blair,et al. Low Cardiorespiratory Fitness and Physical Inactivity as Predictors of Mortality in Men with Type 2 Diabetes , 2000, Annals of Internal Medicine.
[273] Miet Schetz,et al. Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control* , 2003, Critical care medicine.
[274] Christopher P Cannon,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[275] B. Bistrian,et al. Intensive insulin therapy in critically ill patients. , 2002, The New England journal of medicine.
[276] H. Lithell,et al. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data , 1998 .
[277] E. Barrett-Connor,et al. Isolated Postchallenge Hyperglycemia and the Risk of Fatal Cardiovascular Disease in Older Women and Men: The Rancho Bernardo Study , 1998, Diabetes Care.
[278] A. Cowley,et al. Beneficial haemodynamic effects of insulin in chronic heart failure , 2001, Heart.
[279] M. Laakso,et al. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. , 1996, Stroke.
[280] I. U. Haq,et al. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men , 1999, Heart.
[281] G. Murray,et al. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators , 1993 .
[282] T. Lüscher,et al. Enhanced Peroxynitrite Formation Is Associated with Vascular Aging , 2000, The Journal of experimental medicine.
[283] N. Kouchoukos,et al. Risks of bilateral internal mammary artery bypass grafting. , 1990, The Annals of thoracic surgery.
[284] R. Califf,et al. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Aypass Angioplasty Revascularization Investigation (BARI). , 1999, Circulation.
[285] Jun Zhu,et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. , 2005, JAMA.
[286] Z. Naito,et al. Immunohistochemical and morphometric evaluations of coronary atherosclerotic plaques associated with myocardial infarction and diabetes mellitus. , 1998, Journal of atherosclerosis and thrombosis.
[287] L. Chambless,et al. Diabetes, glucose, insulin, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study. , 2005, Diabetes care.
[288] R. Holman,et al. Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29. , 1999, Archives of internal medicine.
[289] G. Van den Berghe,et al. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. , 2003, The Journal of clinical endocrinology and metabolism.
[290] E. Jones,et al. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. , 1999, The Annals of thoracic surgery.
[291] M. Pfeffer,et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.
[292] D. Yellon,et al. Myocardial Protection by Insulin at Reperfusion Requires Early Administration and Is Mediated via Akt and p70s6 Kinase Cell-Survival Signaling , 2001, Circulation research.
[293] H. Ginsberg,et al. The Insulin Resistance Syndrome: Impact on Lipoprotein Metabolism and Atherothrombosis , 2000, Journal of cardiovascular risk.
[294] L. Landsberg. Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why) , 2001, Journal of hypertension.
[295] K. Forrest,et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. , 2003, Diabetes care.
[296] M. Pahor,et al. Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients With Hypertension and NIDDM , 1998, Diabetes Care.
[297] E. Kraegen,et al. Physiological Importance of Deficiency in Early Prandial Insulin Secretion in Non-Insulin-Dependent Diabetes , 1988, Diabetes.
[298] Å. Lernmark,et al. β-Cell Function in Relation to Islet Cell Antibodies During the First 3 Yr After Clinical Diagnosis of Diabetes in Type II Diabetic Patients , 1993, Diabetes Care.
[299] M Gent,et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. , 1991, Journal of the American College of Cardiology.
[300] P. Raskin,et al. Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.
[301] K. Beatt,et al. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. , 1997, Circulation.
[302] G. Dailey,et al. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. , 1995, JAMA.
[303] Seppo Lehto,et al. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. , 2004, Diabetes care.
[304] Gianni Tognoni,et al. Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study. , 2005, Diabetes care.
[305] M. Kaste,et al. Recommendations for the Management of Intracranial Haemorrhage – Part I: Spontaneous Intracerebral Haemorrhage , 2006, Cerebrovascular Diseases.
[306] D. Levy,et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. , 1994, JAMA.
[307] H. Adachi,et al. Is insulin resistance or diabetes mellitus associated with stroke? An 18-year follow-up study. , 2001, Diabetes research and clinical practice.
[308] Tomás Pantoja,et al. Análisis crítico de un artículo Las estatinas reducen la morbi-mortalidad en pacientes de alto riesgo cardiovascular: Heart Protection Study Collaborative Group. (HPS). Lancet 2002; 360: 7-22. , 2003 .
[309] F Bruyninckx,et al. Insulin therapy protects the central and peripheral nervous system of intensive care patients , 2005, Neurology.
[310] T. Orchard. The impact of gender and general risk factors on the occurrence of atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. , 1996, Annals of medicine.
[311] C. Bogardus,et al. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. , 2001, Diabetes care.
[312] E. Hannan,et al. Outcomes of planned home births with certified professional midwives: large prospective study in North America , 2005, BMJ : British Medical Journal.
[313] E. Mannarino,et al. Familial HDL deficiency due to ABCA1 gene mutations with or without other genetic lipoprotein disorders. , 2004, Atherosclerosis.
[314] R. Califf,et al. Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model. , 1997, American heart journal.
[315] H. Tunstall-Pedoe,et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.
[316] K. Fox,et al. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) , 2003, The Lancet.
[317] L H Kuller,et al. Incidence of and risk factors for atrial fibrillation in older adults. , 1997, Circulation.
[318] M. Creager,et al. -.____----.---_-Impaired Nitric Oxide-Mediated Vasodilation in Patients With Non-Insulin-Dependent Diabetes Mellitw , 2016 .
[319] Plamen Nikolov,et al. Economic Costs of Diabetes in the U.S. in 2002 , 2003, Diabetes care.
[320] K. Malmberg. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus , 1997, BMJ.
[321] H. Diener,et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke 1 1 ESPS-2 Writing Committee , 1996, Journal of the Neurological Sciences.
[322] G. Gallus,et al. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. , 2003, Diabetes care.
[323] D. C. Warner,et al. Costs of diabetes in Texas, 1992 , 1996, Diabetes Care.
[324] N. Doll,et al. Impact of Diabetes Mellitus on Cardiac Surgery Outcome , 2003, The Thoracic and cardiovascular surgeon.
[325] B. Gage,et al. Selecting Patients With Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin , 2004, Circulation.
[326] L. Rydén,et al. Effects of Trimetazidine on Left Ventricular Function in Patients with Type 2 Diabetes and Heart Failure , 2004, Journal of cardiovascular pharmacology.
[327] M. Nieminen,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[328] E. Vartiainen,et al. The North Karelia project : 20 year results and experiences , 1995 .
[329] Jaakko Tuomilehto,et al. Disorders of glucose metabolism in acute stroke patients: an underrecognized problem. , 2006, Diabetes care.
[330] B. Davis,et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.
[331] R. de Caterina,et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. , 2004, European heart journal.
[332] T. Valle,et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.
[333] R. Schiele,et al. Intensive treatment of coronary artery disease in diabetic patients in clinical practice: results of the MITRA study , 2003, Acta Diabetologica.
[334] Neil R. Powe,et al. Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus , 2004, Annals of Internal Medicine.
[335] A. Schmidt,et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.
[336] Kurt J Greenlund,et al. Sex Differences in US Mortality Rates for Stroke and Stroke Subtypes by Race/Ethnicity and Age, 1995–1998 , 2002, Stroke.
[337] O. Benavente,et al. Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation , 1999, Annals of Internal Medicine.
[338] F. Cambien,et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes , 1989, Diabetologia.
[339] C. Fry,et al. Science of urinary incontinence Report of a Meeting of Physicians and Scientists, University College London , 1994, The Lancet.
[340] G. Sundkvist,et al. Capillary Blood on Filter Paper for Determination of HbA1c by Ion Exchange Chromatography , 1996, Diabetes Care.
[341] Ralph B D'Agostino,et al. Trends in cardiovascular complications of diabetes. , 2004, JAMA.
[342] R. Jones,et al. Mediastinitis After Coronary Artery Bypass Graft Surgery: Risk Factors and Long‐Term Survival , 1995, Circulation.
[343] D. Wennberg,et al. Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective study. Northern New England Cardiovascular Disease Study Group. , 2001, Journal of the American College of Cardiology.
[344] G Hu,et al. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study , 2004, Diabetologia.
[345] C. Edwards. International Textbook of Diabetes Mellitus , 2004 .
[346] J. Wilberger,et al. The impact of hyperglycemia on patients with severe brain injury. , 2005, The Journal of trauma.
[347] Gerardo Heiss,et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study , 1999, The Lancet.
[348] J. Tuomilehto,et al. Occupational, Commuting, and Leisure-Time Physical Activity in Relation to Total and Cardiovascular Mortality Among Finnish Subjects With Type 2 Diabetes , 2004, Circulation.
[349] R. Holman,et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.
[350] J. Tuomilehto,et al. The major diabetes prevention trials , 2003, Current diabetes reports.
[351] P. Iozzo,et al. Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. , 2002, Diabetes.
[352] Oliver Schnell,et al. Intensification of therapeutic approaches reduces mortality in diabetic patients with acute myocardial infarction: the Munich registry. , 2004, Diabetes care.
[353] L. Piegas,et al. Metabolic Modulation of Acute Myocardial Infarction The ECLA Glucose-Insulin-Potassium Pilot Trial , 1998 .
[354] W. Hiatt,et al. Medical treatment of peripheral arterial disease and claudication. , 2001, The New England journal of medicine.
[355] M. Sclavo. [Physical activity and risk for cardiovascular events in diabetic women]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.
[356] R Dietz,et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. , 2000, JAMA.
[357] E. Mayer-Davis,et al. Nutrition and prevention of type 2 diabetes. , 2003, Annual review of nutrition.
[358] R. Collins,et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.
[359] V. Salomaa,et al. Glucose tolerance and blood pressure: long term follow up in middle aged men. , 1991, BMJ.
[360] Steven Snapinn,et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol , 2002, The Lancet.
[361] 康生 大久保,et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study , 1995 .
[362] M. Laakso,et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.
[363] W. Koenig,et al. The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? , 2000, Diabetologia.
[364] Andrew Briggs,et al. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20 536 individuals , 2005, The Lancet.
[365] M. Engelgau,et al. Screening for type 2 diabetes. , 2000, Diabetes care.
[366] R. Narayan,et al. The influence of diabetes mellitus on outcome from subarachnoid hemorrhage. , 1991, Diabetes research.
[367] M. Laakso,et al. Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with Type II diabetes , 2000, Diabetologia.
[368] John H Fuller,et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.
[369] M. Hanefeld,et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. , 2004, The Journal of clinical endocrinology and metabolism.
[370] R B D'Agostino,et al. Probability of stroke: a risk profile from the Framingham Study. , 1991, Stroke.
[371] Po Box,et al. Excess risk of fatal coronary heart disease associated with diabetes in men and women:meta-analysis of 37 prospective cohort studies , 2006 .
[372] G. Habib,et al. Silent myocardial ischemia in patients with diabetes: who to screen. , 1999, Diabetes care.
[373] W. Kannel,et al. Diabetes and cardiovascular disease. The Framingham study. , 1979, JAMA.
[374] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[375] H Wedel,et al. Infarction : Long-Term Results From the Diabetes and Insulin-Glucose Infusion Conventionally Treated Patients With Diabetes Mellitus and Acute Myocardial Glycometabolic State at Admission : Important Risk Marker of Mortality in , 1999 .
[376] K. Malmberg,et al. Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction. , 2003, European heart journal.
[377] I. Palacios,et al. Argentine Randomized Study: Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators. , 2001, Journal of the American College of Cardiology.
[378] M. Muggeo,et al. Cardiovascular Disease and Its Risk Factors in IDDM in Europe , 1996, Diabetes Care.
[379] U. Das. Is insulin an endogenous cardioprotector? , 2002, Critical care.
[380] E. Topol,et al. Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. , 2004, European heart journal.
[381] G. Davey Smith,et al. Physical activity and cause‐specific mortality in men with Type 2 diabetes/impaired glucose tolerance: evidence from the Whitehall study , 2002, Diabetic medicine : a journal of the British Diabetic Association.
[382] M. Turina,et al. [Percutaneous transluminal dilatation of chronic coronary stenoses. First experiences]. , 1978, Swiss medical weekly.
[383] N. Vaughan. Report of the 8th EASD-DOIT Study Group Workshop "Decision Support in Diabetes Care" Stirling Royal Infirmary, Stirling, UK, 7-8 September 2001. , 2002, Diabetologia.
[384] J. Stengård,et al. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.
[385] M. Hanefeld,et al. A long‐term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double‐blind, parallel‐group comparison trial , 2005, Diabetic medicine : a journal of the British Diabetic Association.
[386] J. Shaw,et al. Follow-up report on the diagnosis of diabetes mellitus. , 2003, Diabetes care.
[387] Bari Investigators. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. , 2000, Journal of the American College of Cardiology.
[388] I. S. Klemasev. Myocardial infarction in patients with diabetes mellitus. , 1967 .
[389] F. Murad,et al. Protein Nitration in Cardiovascular Diseases , 2002, Pharmacological Reviews.
[390] J. Ottervanger,et al. Comparison of myocardial perfusion after successful primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction with versus without diabetes mellitus. , 2005, The American journal of cardiology.
[391] Deepak L. Bhatt,et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. , 2000, Journal of the American College of Cardiology.
[392] A. Sniderman,et al. Low Density Lipoprotein: A METABOLIC PATHWAY FOR RETURN OF CHOLESTEROL TO THE SPLANCHNIC BED , 1978 .
[393] D. Singer,et al. Antithrombotic therapy in atrial fibrillation. , 2001, Chest.
[394] M. Laakso,et al. Structure and Costs of Health Care of Diabetic Patients in Finland , 1996, Diabetes Care.
[395] D. Ziegler,et al. Stroke in patients with diabetes mellitus , 2004, Diabetes/metabolism research and reviews.
[396] M. Laakso,et al. Hyperglycemia and cardiovascular disease in type 2 diabetes. , 1999, Diabetes.
[397] G. Reaven. Banting lecture 1988. Role of insulin resistance in human disease. , 1988, Diabetes.
[398] B. Danielsson,et al. Dicyclomine hydrochloride in infantile colic. , 1985, British medical journal.
[399] J. Tuomilehto,et al. Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction , 2005, Diabetologia.
[400] J Herlitz,et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. , 2005, European heart journal.
[401] B. Jönsson,et al. Revealing the cost of Type II diabetes in Europe , 2002, Diabetologia.
[402] D. Ewing,et al. The natural history of diabetic autonomic neuropathy. , 1980, The Quarterly journal of medicine.
[403] M. Pfeffer,et al. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. , 2003, Journal of the American College of Cardiology.
[404] F. Cappuccio,et al. Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice: cross sectional population based study , 2002, BMJ : British Medical Journal.
[405] M. Apkon,et al. Hyperglycemia in Critically Ill Children: 21 , 2005 .
[406] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[407] KazuomiKario,et al. Activation of Tissue Factor–Induced Coagulation and Endothelial Cell Dysfunction in Non–Insulin-Dependent Diabetic Patients With Microalbuminuria , 1995 .
[408] G. Nijpels,et al. The performance of a risk score as a screening test for undiagnosed hyperglycemia in ethnic minority groups: data from the 1999 health survey for England. , 2004, Diabetes care.
[409] T. Bowker,et al. Difference in the mortality of the CABRI diabetic and nondiabetic populations and its relation to coronary artery disease and the revascularization mode. , 2001, The American journal of cardiology.
[410] I. Hirsch,et al. Reduced Plasma Peroxyl Radical Trapping Capacity and Increased Susceptibility of LDL to Oxidation In Poorly Controlled IDDM , 1994, Diabetes.
[411] Tseng Chin-Hsiao. The Costs of Diabetes , 2000 .
[412] G. Hu,et al. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes , 2003, Diabetologia.
[413] S. Lillioja,et al. Relationship between degree of obesity and in vivo insulin action in man. , 1985, The American journal of physiology.
[414] A. Sniderman,et al. Hypertriglyceridemic HyperapoB: The Unappreciated Atherogenic Dyslipoproteinemia in Type 2 Diabetes Mellitus , 2001, Annals of Internal Medicine.
[415] J. Meigs,et al. Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. , 2000, American journal of epidemiology.
[416] T. B. Investigators,et al. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) , 1997, Circulation.
[417] Paul Zimmet,et al. The metabolic syndrome—a new worldwide definition , 2005, The Lancet.
[418] N Freemantle,et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. , 1999, BMJ.
[419] N. Maurits,et al. Admitting Acute Ischemic Stroke Patients to a Stroke Care Monitoring Unit Versus a Conventional Stroke Unit: A Randomized Pilot Study , 2003, Stroke.
[420] Daniel Levy,et al. Arrhythmias: abstractA risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community. The Framingham Heart Study☆ , 2003 .
[421] J. Tu,et al. Risk Factors for Death or Stroke After Carotid Endarterectomy: Observations From the Ontario Carotid Endarterectomy Registry , 2003, Stroke.
[422] D. Faxon,et al. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. , 1996, Circulation.
[423] J. Remes,et al. Incidence of heart failure in eastern Finland: a population-based surveillance study. , 1992, European heart journal.
[424] V. Fuster,et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conference , 2001, Circulation.
[425] H. Gerstein,et al. The Economic Cost of Diabetes in Canada, 1998 , 2002 .
[426] H. Taegtmeyer. Cardiac metabolism as a target for the treatment of heart failure. , 2004, Circulation.
[427] Ilse Vanhorebeek,et al. Intensive insulin therapy protects the endothelium of critically ill patients. , 2005, The Journal of clinical investigation.
[428] P. Deedwania,et al. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. , 2005, American heart journal.
[429] E. Guallar,et al. Meta-Analysis of Randomized Educational and Behavioral Interventions in Type 2 Diabetes , 2003, The Diabetes educator.
[430] A. Bernstein,et al. A comparison of risk factors for recurrent TIA and stroke in patients diagnosed with TIA , 2003, Neurology.
[431] E. J. Brown,et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.
[432] N. Gratsianskiĭ. [Expert consensus document on the use of antiplatelet agents]. , 2004, Kardiologiia.
[433] G. Paolisso,et al. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. , 1997, Diabetes & metabolism.
[434] Y. Kaneda,et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage , 2000, Nature.
[435] M. Hanefeld,et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. , 2004, European heart journal.
[436] D. Toni,et al. Does hyperglycaemia play a role on the outcome of acute ischaemic stroke patients? , 1992, Journal of Neurology.
[437] F. Fernández‐Avilés,et al. Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients: The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial , 2005, Circulation.
[438] S. Fowler,et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .
[439] P. Whelton,et al. Risk of End-stage Renal Disease in Diabetes Mellitus: A Prospective Cohort Study of Men Screened for MRFIT , 1997 .
[440] James Stephen Krinsley,et al. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. , 2003, Mayo Clinic proceedings.
[441] L. Wallentin,et al. Early revascularisation and 1-year survival in 14-day survivors of acute myocardial infarction: a prospective cohort study , 2002, The Lancet.
[442] A. Manto,et al. Blunted erythropoietin response to anemia in type 1 diabetic patients. , 1999, Diabetes care.
[443] Oluf Pedersen,et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.
[444] E. Antman. Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: appropriate interpretation of the guidelines. , 2003, American heart journal.
[445] E. Frank. Book Review Women's Mental Health: A Life-Cycle Approach Edited by Sarah E. Romans and Mary V. Seeman. 414 pp. Philadelphia, Lippincott Williams & Wilkins, 2005. $59.95. 0-7817-5129-2 , 2005 .
[446] T. Deckert,et al. Prognosis of diabetics with diabetes onset before the age of thirty-one. I. Survival, causes of death, and complications. , 1978, Diabetologia.
[447] Deepak L. Bhatt,et al. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. , 2004, Archives of internal medicine.
[448] S. Milstien,et al. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. , 1999, Biochemical and biophysical research communications.
[449] Markolf Hanefeld,et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. , 2003, JAMA.
[450] Pd redaction. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. , 2002, Diabetes care.
[451] S. Haffner,et al. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? , 2004, Diabetes care.
[452] T. Hedner,et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension–2 , 2000, Journal of hypertension.
[453] M. Gheorghiade,et al. &bgr;-Blockers in the Post-Myocardial Infarction Patient , 2002, Circulation.
[454] Carl J Caspersen,et al. Relationship of walking to mortality among US adults with diabetes. , 2003, Archives of internal medicine.
[455] S. Fava,et al. The Prognostic Value of Blood Glucose in Diabetic Patients with Acute Myocardial Infarction , 1996, Diabetic medicine : a journal of the British Diabetic Association.
[456] S. Yusuf,et al. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53. , 2000 .
[457] S. Haffner,et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. , 1999, Archives of internal medicine.
[458] H. Yki-Järvinen. Comparison of insulin regimens for patients with type 2 diabetes , 2000 .
[459] S. Fowler,et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. , 2005, Diabetes care.
[460] T. Blanck,et al. VOLATILE ANESTHETIC DEPRESSION OF CALCIUM CHANNELS IN BRAIN MEMBRANES , 1989 .
[461] L. Opie,et al. Propranolol and experimental myocardial infarction: substrate effects. , 1976, Postgraduate medical journal.
[462] I. O'Brien,et al. The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. , 1991, The Quarterly journal of medicine.
[463] M. Marre,et al. Efficacy of diuretics and beta-blockers in diabetic hypertensive patients. Results from a meta-analysis. The INDANA Steering Committee. , 2000, Diabetes care.
[464] R. Califf,et al. Influence of Diabetes Mellitus on Clinical Outcome in the Thrombolytic Era of Acute Myocardial Infarction , 1997 .
[465] D. Singer,et al. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is … or is it? , 1997, The Lancet.
[466] W C Willett,et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. , 2001, Archives of internal medicine.
[467] E. Feskens,et al. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. , 2001, Archives of internal medicine.
[468] E. Barrett,et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. , 2004, Diabetes care.
[469] P. Clemmensen,et al. The prognostic value of pre-discharge exercise testing after myocardial infarction treated with either primary PCI or fibrinolysis: a DANAMI-2 sub-study. , 2004, European heart journal.
[470] Mark Hargreaves,et al. Adrenaline increases skeletal muscle glycogenolysis, pyruvate dehydrogenase activation and carbohydrate oxidation during moderate exercise in humans , 2001, The Journal of physiology.
[471] P. Bennett,et al. Medial arterial calcification and its association with mortality and complications of diabetes , 1988, Diabetologia.
[472] H. Barnhart,et al. Effectiveness of revascularization in the Emory angioplasty versus surgery trial. A randomized comparison of coronary angioplasty with bypass surgery. , 1996, Circulation.
[473] S. Priori,et al. 2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension , 2004, Heart Drug.
[474] J. Leahy. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial , 2007 .
[475] F. Cosentino,et al. Diabetes and Inflammation , 2004, Herz.
[476] T. Chalmers,et al. A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. , 1994, International angiology : a journal of the International Union of Angiology.
[477] R. Macko,et al. Thrombomodulin deficiency in human diabetic nerve microvasculature. , 2002, Diabetes.
[478] N. Tofil,et al. Should you treat high glucose? A critical appraisal of "Persistent hyperglycemia in critically ill children" by Faustino and Apkon. (J Pediatr 2005; 146:30-34) , 2007 .
[479] K. Lachapelle,et al. Maintenance of Normoglycemia During Cardiac Surgery , 2004, Anesthesia and analgesia.
[480] A. Chinaglia,et al. QT interval, cardiovascular risk factors and risk of death in diabetes , 2004, Journal of endocrinological investigation.
[481] S. Yusuf,et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. , 1992, Circulation.
[482] J. Evans,et al. ACE Inhibitor Use Is Associated With Hospitalization for Severe Hypoglycemia in Patients With Diabetes , 1997, Diabetes Care.
[483] G. Van den Berghe,et al. Metabolic, endocrine, and immune effects of stress hyperglycemia in a rabbit model of prolonged critical illness. , 2003, Endocrinology.
[484] J. Beckman,et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I , 2013, European heart journal.
[485] Robert L. Frye,et al. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. , 1996, The New England journal of medicine.
[486] R. Bucala,et al. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. , 2002, Diabetes care.
[487] Dick M. Goedhart,et al. Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention--a Lescol Intervention Prevention Study (LIPS) substudy. , 2005, American heart journal.
[488] Eber,et al. Effects of intensified lifestyle modification on the need for further revascularization after coronary angioplasty , 1999, European journal of clinical investigation.
[489] R M Heethaar,et al. Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. , 2001, Diabetes care.
[490] L. Rydén,et al. Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients. , 1999, Diabetes care.
[491] A. Dominiczak,et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.
[492] R McBride,et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. , 1999, Stroke.
[493] J. Hokanson,et al. Plasma Triglyceride Level is a Risk Factor for Cardiovascular Disease Independent of High-Density Lipoprotein Cholesterol Level: A Metaanalysis of Population-Based Prospective Studies , 1996, Journal of cardiovascular risk.
[494] B. Howard,et al. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[495] J. Tuomilehto,et al. WHO MONICA Project: assessing CHD mortality and morbidity. , 1989, International journal of epidemiology.
[496] W. Weaver,et al. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. , 2003, American heart journal.
[497] S. Colagiuri. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. , 2004, European heart journal.
[498] B. Howard,et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: the Strong Heart Study. , 2003, Diabetes care.
[499] A. Barcelo,et al. The cost of diabetes in Latin America and the Caribbean. , 2003, Bulletin of the World Health Organization.
[500] Richard Hellman,et al. American College of Endocrinology position statement on the insulin resistance syndrome. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[501] J. Tayek,et al. Cortisol increases gluconeogenesis in humans: its role in the metabolic syndrome. , 2001, Clinical science.
[502] F. Sones,et al. Myocardial revascularization by internal mammary artery implant procedures. Clinical experience. , 1967, The Journal of thoracic and cardiovascular surgery.
[503] B. Balkau,et al. Comment on the provisional report from the WHO consultation , 1999, Diabetic medicine : a journal of the British Diabetic Association.
[504] Y. Suematsu,et al. Predictive risk factors for delayed extubation in patients undergoing coronary artery bypass grafting , 2000, Heart and Vessels.
[505] B. Davis,et al. Uniformity of captopril benefit in the SAVE study : subgroup analysis , 1994 .
[506] M. Hanefeld,et al. Das Metabolische Syndrom , 2006 .
[507] Shah Ebrahim,et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2003 .
[508] S. Schmidt-Schweda,et al. First clinical trial with etomoxir in patients with chronic congestive heart failure. , 2000, Clinical science.
[509] S. Genuth,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.
[510] W. Cherng,et al. Modification of left ventricular isovolumic relaxation time during dobutamine echocardiography as a diagnostic method for ischemic heart disease. , 1997, Changgeng yi xue za zhi.
[511] P. Wolf,et al. Black-white differences in stroke incidence in a national sample. The contribution of hypertension and diabetes mellitus. , 1990, JAMA.
[512] R. Kahn,et al. The metabolic syndrome: time for a critical appraisal , 2005, Diabetologia.
[513] S. Punsar,et al. Glucose tolerance and coronary heart disease: Helsinki policemen study. , 1979, Journal of chronic diseases.
[514] R. Hamman,et al. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. , 1995, Circulation.
[515] T. Valle,et al. Physical activity, body mass index, and risk of type 2 diabetes in patients with normal or impaired glucose regulation. , 2004, Archives of internal medicine.
[516] L. Deckelbaum,et al. Effect of plasma insulin level on myocardial blood flow and its mechanism of action. , 2000, The American journal of cardiology.
[517] D. Clement. A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .
[518] N. Lamblin,et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. , 2004, European heart journal.
[519] Sarah Parish,et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.
[520] A. Alavi,et al. Relation of hyperglycemia early in ischemic brain infarction to cerebral anatomy, metabolism, and clinical outcome , 1990, Annals of neurology.
[521] R. Cohen,et al. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. , 1991, The Journal of clinical investigation.
[522] H. Diener,et al. European Stroke Initiative Recommendations for Stroke Management – Update 2003 , 2003, Cerebrovascular Diseases.
[523] P. Iozzo,et al. Mismatch between insulin-mediated glucose uptake and blood flow in the heart of patients with Type II diabetes , 2002, Diabetologia.
[524] E. Lengerich,et al. The burden of diabetes in North Carolina. , 1995, North Carolina medical journal.
[525] Ken Williams,et al. National Cholesterol Education Program Versus World Health Organization Metabolic Syndrome in Relation to All-Cause and Cardiovascular Mortality in the San Antonio Heart Study , 2004, Circulation.
[526] Arshag D Mooradian,et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. , 2003, Diabetes care.
[527] R. Holman,et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.
[528] Jeffrey L Carson,et al. Diabetes mellitus increases short-term mortality and morbidity in patients undergoing coronary artery bypass graft surgery. , 2002, Journal of the American College of Cardiology.
[529] M. Olschewski,et al. Glucose-insulin-potassium in cardiac surgery: a meta-analysis. , 2004, The Annals of thoracic surgery.
[530] J. Salmerón,et al. Diabetes in Mexico--a serious and growing problem. , 1992, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.
[531] A. Vinik,et al. Recognizing and treating diabetic autonomic neuropathy. , 2001, Cleveland Clinic journal of medicine.
[532] M. Woodward,et al. Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .
[533] M. Laakso,et al. Dyslipidemia and Hyperglycemia Predict Coronary Heart Disease Events in Middle-Aged Patients With NIDDM , 1997, Diabetes.
[534] J. Leahy. The Metabolic Syndrome: Time for a Critical Appraisal: Joint Statement From the American Diabetes Association and the European Association for the Study of Diabetes , 2006 .
[535] M. Dennis. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .
[536] H. Löwel,et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: Target populations for efficient screening. The KORA survey 2000 , 2003, Diabetologia.
[537] K. Yano,et al. Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program. , 1999, Diabetes care.
[538] L. Rydén,et al. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies. , 1989, European heart journal.
[539] S. Arikian,et al. THE COST‐EFFECTIVENESS OF DOXAZOSIN FOR THE TREATMENT OF HYPERTENSION IN TYPE II DIABETIC PATIENTS IN THE UK AND ITALY , 2001, International journal of clinical practice.
[540] M. Laakso,et al. Non‐Insulin‐Dependent Diabetes and Its Metabolic Control Are Important Predictors of Stroke in Elderly Subjects , 1994, Stroke.
[541] K. Flegal,et al. Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in U.S. Adults: The Third National Health and Nutrition Examination Survey, 1988–1994 , 1998, Diabetes Care.
[542] J. Staessen,et al. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. , 2000, Archives of internal medicine.
[543] Peter Jüni,et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. , 2006, American heart journal.
[544] E. Rimm,et al. Physical Activity in Relation to Cardiovascular Disease and Total Mortality Among Men With Type 2 Diabetes , 2003, Circulation.
[545] David R. Wood,et al. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. , 2001, European heart journal.
[546] M. Engelgau,et al. Prevention of type 2 diabetes: issues and strategies for identifying persons for interventions. , 2004, Diabetes technology & therapeutics.
[547] K. Borch-Johnsen. The new classification of diabetes mellitus and IGT: a critical approach. , 2001, Experimental and clinical endocrinology & diabetes.
[548] D. Chinkes,et al. Association of hyperglycemia with increased mortality after severe burn injury. , 2001, The Journal of trauma.
[549] Maria Inês Schmidt,et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. , 2005, Diabetes care.
[550] Timothy W. Evans,et al. Glucose Control and Mortality in Critically Ill Patients , 2003 .
[551] M. Laakso,et al. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. , 1996, Stroke.
[552] L. Wallentin,et al. A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study. , 2002, Journal of the American College of Cardiology.
[553] B. Pitt,et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .
[554] L. Hsu,et al. Clinical outcomes of patients with diabetes mellitus and acute myocardial infarction treated with primary angioplasty or fibrinolysis , 2002, Heart.
[555] P. Nilsson,et al. Hypertension in diabetes: trends in clinical control in repeated large-scale national surveys from Sweden , 2003, Journal of Human Hypertension.
[556] T. Vos,et al. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. , 2003, American heart journal.
[557] W. O’Neill. Multivessel balloon angioplasty should be abandoned in diabetic patients! , 1998, Journal of the American College of Cardiology.
[558] Yingxing Wu,et al. Effect of hyperglycemia and continuous intravenous insulin infusions on outcomes of cardiac surgical procedures: the Portland Diabetic Project. , 2004, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[559] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[560] Jerome Sacks,et al. Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry. , 2002, Journal of the American College of Cardiology.
[561] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[562] M. Simoons,et al. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. , 2005, European heart journal.
[563] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.
[564] G. Chatellier,et al. The Framingham prediction rule is not valid in a European population of treated hypertensive patients , 2002, Journal of hypertension.
[565] G. De Backer,et al. Predictive value of classical risk factors and their control in coronary patients: a follow-up of the EUROASPIRE I cohort , 2003, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[566] H. Gerstein,et al. Stress Hyperglycemia and Prognosis of Stroke in Nondiabetic and Diabetic Patients: A Systematic Overview , 2001, Stroke.
[567] W. Kannel,et al. The natural history of congestive heart failure: the Framingham study. , 1971, The New England journal of medicine.
[568] M. Hill,et al. Altered transcriptional regulation of phosphoenolpyruvate carboxykinase in rats following endotoxin treatment. , 1991, The Journal of clinical investigation.
[569] N. Day,et al. Association of Hemoglobin A1c with Cardiovascular Disease and Mortality in Adults: The European Prospective Investigation into Cancer in Norfolk , 2004, Annals of Internal Medicine.
[570] S. Dimmeler,et al. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. , 2001, The Journal of clinical investigation.
[571] J. Kampine,et al. Increased intraoperative cardiovascular morbidity in diabetics with autonomic neuropathy. , 1987, Anesthesiology.
[572] J. Tuomilehto,et al. Consequences of the new diagnostic criteria for diabetes in older men and women. DECODE Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe). , 1999, Diabetes care.
[573] L. Gaal,et al. Assessing the impact of complications on the costs of Type II diabetes , 2002, Diabetologia.
[574] R. Frye,et al. Coronary Bypass Graft Patency in Patients With Diabetes in the Bypass Angioplasty Revascularization Investigation (BARI) , 2002, Circulation.
[575] G. Specchia,et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology* , 2002 .
[576] G. Reaven. Role of Insulin Resistance in Human Disease , 1988, Diabetes.
[577] Ames,et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.
[578] D. Rader,et al. Lipases and HDL metabolism , 2002, Trends in Endocrinology & Metabolism.
[579] I. Godsland,et al. Loss of beta cell function as fasting glucose increases in the non-diabetic range , 2004, Diabetologia.
[580] B. Howard,et al. Effects of Diet and Exercise in Preventing NIDDM in People With Impaired Glucose Tolerance: The Da Qing IGT and Diabetes Study , 1997, Diabetes Care.
[581] P. Zimmet,et al. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.
[582] D. Singer,et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.
[583] Hough Fs. Type 2 Diabetes and the metabolic syndrome , 2007 .
[584] J. Fuller,et al. International variations in cardiovascular mortality associated with diabetes mellitus: the WHO Multinational Study of Vascular Disease in Diabetes. , 1996, Annals of medicine.
[585] A. Whittemore. Presidential address: a team for the 21st century: the vascular center. , 2000, Journal of vascular surgery.
[586] E. Gilpin,et al. Diabetic patients and beta-blockers after acute myocardial infarction. , 1990, European heart journal.
[587] Claude Colette,et al. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). , 2003, Diabetes care.
[588] P. Nilsson,et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. , 2002, Diabetes & metabolism.
[589] Jaakko Tuomilehto,et al. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. , 2003, Diabetes care.
[590] A. Gray,et al. The Cost of Insulin‐dependent Diabetes Mellitus (IDDM) in England and Wales , 1995, Diabetic medicine : a journal of the British Diabetic Association.
[591] M W Knuiman,et al. Prediction of coronary heart disease mortality in Busselton, Western Australia: an evaluation of the Framingham, national health epidemiologic follow up study, and WHO ERICA risk scores. , 1997, Journal of epidemiology and community health.
[592] M. Laakso,et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.
[593] Strokepreventioninatrialfibri. The stroke prevention in atrial fibrillation III study: rationale, design, and patient features. , 1997, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[594] D. Holmes,et al. Lessons from the Pooled Outcome of the PAMI, ZWOLLE and Mayo Clinic Randomized Trials of Primary Angioplasty Versus Thrombolytic Therapy of Acute Myocardial Infarction. , 1998, The Journal of invasive cardiology.
[595] E. Topol,et al. The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics. , 1999, Journal of the American College of Cardiology.
[596] Sankey V. Williams,et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). , 2003, Journal of the American College of Cardiology.
[597] G. Rose,et al. RISK OF STROKE IN NON-RHEUMATIC ATRIAL FIBRILLATION , 1987, The Lancet.
[598] M. Franz,et al. The evidence for the effectiveness of medical nutrition therapy in diabetes management. , 2002, Diabetes care.
[599] K. Narayan,et al. Epidemiology and geography of type 2 diabetes mellitus , 2004 .
[600] C. Bulpitt,et al. Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension , 1999 .
[601] J. Shaw,et al. A new IDF worldwide definition A new IDF worldwide definition of the metabolic syndrome: of the metabolic syndrome: the rationale and the results , 2005 .
[602] James W. Anderson,et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). , 2002, Archives of internal medicine.
[603] M. Hadamitzky,et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. , 1998, Journal of the American College of Cardiology.
[604] J. Sowers,et al. Diabetes and cardiovascular disease. , 1999, Diabetes care.
[605] J. Tuomilehto,et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. , 2004, Archives of internal medicine.
[606] L. Niskanen,et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.
[607] S. Yusuf,et al. Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry , 2000, Circulation.
[608] C. Bogardus,et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. , 1999, The Journal of clinical investigation.
[609] M. Laakso. Perspectives in Diabetes Hyperglycemia and Cardiovascular Disease in me 2 Diabetes , 1999 .
[610] J. Ottervanger,et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. , 1999, The New England journal of medicine.
[611] M. Mclean,et al. Insulin infusion therapy for myocardial infarction , 2006, Expert opinion on pharmacotherapy.
[612] Pd redaction. The prevention or delay of type 2 diabetes. , 2003, Caring : National Association for Home Care magazine.
[613] L. Niskanen,et al. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. , 2001, Diabetes care.
[614] AntonioCeriello,et al. Is Oxidative Stress the Pathogenic Mechanism Underlying Insulin Resistance, Diabetes, and Cardiovascular Disease? The Common Soil Hypothesis Revisited , 2004 .
[615] D. Bacquer,et al. Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys , 2004, Diabetologia.
[616] J. McKendry. Direct costs of diabetes care: a survey in Ottawa, Ontario 1986. , 1989, Canadian journal of public health = Revue canadienne de sante publique.
[617] O. Schnell,et al. A new look at the heart in diabetes mellitus: from ailing to failing , 2000, Diabetologia.
[618] E. Braunwald. Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. , 1997, The New England journal of medicine.
[619] A. Vinik,et al. Platelet dysfunction in type 2 diabetes. , 2001, Diabetes care.
[620] J Herlitz,et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. , 1995, Journal of the American College of Cardiology.
[621] J. Segall. Strategy of prevention: lessons from cardiovascular disease , 1981, British medical journal.
[622] A. Folsom,et al. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. , 1999, Diabetes care.
[623] C. Wolf‐peeters,et al. Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients , 2005, The Lancet.
[624] J. Bassand. GUSTO (Global Utilization of Streptokinase and Tissue plasminogen activator in Occluded arteries): logic wins at last. , 1994, European heart journal.
[625] Jessie Venegas. The Finnish Diabetes Prevention Study , 2008 .
[626] K. Asplund,et al. Diabetes as a risk factor for stroke. A population perspective , 1995, Diabetologia.
[627] Å. Lernmark,et al. Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. , 1993, Diabetes care.
[628] R. D'Agostino,et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. , 2001, JAMA.
[629] F. Gao,et al. Ischemia-Reperfusion : The Roles of PI 3-Kinase , Akt , and Endothelial Nitric Oxide Nitric Oxide Mediates the Antiapoptotic Effect of Insulin in Myocardial , 2002 .
[630] N. Cox,et al. Diabetes mellitus and early mortality from stroke , 1985, British medical journal.
[631] Peter Libby,et al. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. , 2002, JAMA.
[632] D. Ewing,et al. Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients , 1991, Diabetologia.
[633] Dieter Mesotten,et al. Contribution of circulating lipids to the improved outcome of critical illness by glycemic control with intensive insulin therapy. , 2004, The Journal of clinical endocrinology and metabolism.
[634] GerdAssmann,et al. Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Münster (PROCAM) Study , 2002 .
[635] J. Tuomilehto,et al. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? , 2003, Diabetes care.
[636] N. Poulter,et al. The anglo-scandinavian cardiac outcomes trial (ASCOT) , 1998 .
[637] R. Califf,et al. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. , 1996, Journal of the American College of Cardiology.
[638] J. Tuomilehto,et al. Incidence of cardiovascular disease in Type 1 (insulin-dependent) diabetic subjects with and without diabetic nephropathy in Finland , 1998, Diabetologia.
[639] Y. Seino,et al. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. , 2004, Diabetes research and clinical practice.
[640] P. Tsao,et al. Impaired Nitric Oxide Synthase Pathway in Diabetes Mellitus: Role of Asymmetric Dimethylarginine and Dimethylarginine Dimethylaminohydrolase , 2002, Circulation.
[641] F. Zannad,et al. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. Epidémiologie de l'Insuffisance Cardiaque Avancée en Lorraine. , 1999, Journal of the American College of Cardiology.
[642] American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control * , 2004 .
[643] T. Rea,et al. Diabetes, glucose level, and risk of sudden cardiac death. , 2005, European heart journal.
[644] A. Swai,et al. Must diabetes be a fatal disease in Africa? Study of costs of treatment. , 1992, BMJ.
[645] R. D'Agostino,et al. Sudden coronary death in women. , 1998, American heart journal.
[646] S. Yusuf,et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. , 2005, JAMA.
[647] Matilde. Peer education spotlight--meet Matilde. Interview by Amy Jo Harzke. , 1998, Positive Directions news : a support and information network of people with HIV/AIDS, their families, friends and providers.
[648] R. Califf,et al. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. , 1997, Circulation.
[649] G. Moneta,et al. Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes , 2007 .
[650] I. Piña. Valsartan in acute myocardial infarction trial. , 2004, Current cardiology reports.
[651] J S Beckman,et al. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. , 1996, The American journal of physiology.
[652] E. Eschwège,et al. The cost of diabetes in France. , 1988, Health policy.
[653] Curt D. Furberg,et al. Incidence, Manifestations, and Predictors of Brain Infarcts Defined by Serial Cranial Magnetic Resonance Imaging in the Elderly: The Cardiovascular Health Study , 2002, Stroke.
[654] J. Halter,et al. Pathophysiology of Insulin Secretion in Non-insulin-dependent Diabetes Mellitus , 1984, Diabetes Care.
[655] L. Rydén,et al. Diabetes mellitus and congestive heart failure. Further knowledge needed. , 1999, European heart journal.
[656] G. Thorgeirsson,et al. Glucose tolerance and blood pressure in a population-based cohort study of males and females: the Reykjavik Study , 1995, Journal of hypertension.
[657] L. Rydén,et al. Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study. , 1997, Cardiovascular research.
[658] Nancy R Cook,et al. C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.
[659] L. Rydén,et al. Management of coronary artery disease in patients with and without diabetes mellitus. Acute management reasonable but secondary prevention unacceptably poor: a report from the Euro Heart Survey on Diabetes and the heart , 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[660] R. Schrier,et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. , 1998, The New England journal of medicine.
[661] A. Boulton,et al. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. , 2001, Diabetes care.
[662] Alice Stanton,et al. Differential Impact of Blood Pressure–Lowering Drugs on Central Aortic Pressure and Clinical Outcomes: Principal Results of the Conduit Artery Function Evaluation (CAFE) Study , 2006, Circulation.
[663] M. Lai,et al. Direct costs-of-illness of patients with diabetes mellitus in Taiwan. , 2001, Diabetes research and clinical practice.
[664] H. Keen,et al. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes , 2001, Diabetologia.
[665] S. Wild,et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.
[666] H. Yki-Järvinen. Glucose toxicity. , 1992, Endocrine reviews.
[667] H. L. Bleich,et al. The Harvard Cooperative Stroke Registry , 1978, Neurology.
[668] G A Colditz,et al. The economic costs of non-insulin-dependent diabetes mellitus. , 1989, JAMA.
[669] Claude Lenfant,et al. Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[670] F. Game,et al. Coronary heart disease risk assessment in diabetes mellitus–‐a comparison of PROCAM and Framingham risk assessment functions , 2001, Diabetic medicine : a journal of the British Diabetic Association.
[671] S. Juvela,et al. Risk factors for multiple intracranial aneurysms. , 2000, Stroke.
[672] J. Mehilli,et al. Drug-eluting Stents in Diabetic Patients , 2006 .
[673] Bernard Rosner,et al. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. , 1990, The New England journal of medicine.
[674] P Glasziou,et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.
[675] P Ducimetière,et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. , 2003, European heart journal.
[676] P. Whelton,et al. Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. , 1997, JAMA.
[677] A. Vinik,et al. Diabetic Cardiovascular Autonomic Neuropathy , 2007, Circulation.
[678] B. Davis,et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. , 1996, JAMA.
[679] L. Suzuki,et al. Diabetes accelerates smooth muscle accumulation in lesions of atherosclerosis: lack of direct growth-promoting effects of high glucose levels. , 2001, Diabetes.
[680] A. Rovlias,et al. The influence of hyperglycemia on neurological outcome in patients with severe head injury. , 2000, Neurosurgery.
[681] G. Pogátsa. Metabolic energy metabolism in diabetes: therapeutic implications. , 2001, Coronary artery disease.
[682] J. Neaton,et al. Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.
[683] Vilmundur Gudnason,et al. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. , 2005, Diabetes care.
[684] R. Frye,et al. Comparison of survival after successful percutaneous coronary intervention of patients with diabetes mellitus receiving insulin versus those receiving only diet and/or oral hypoglycemic agents. , 2004, American Journal of Cardiology.
[685] Thomas Hedner,et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study , 2000, The Lancet.
[686] E. Vartiainen,et al. Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population. , 1996, Stroke.
[687] S. Haffner,et al. Prospective Analysis of The Insulin-Resistance Syndrome (Syndrome X) , 1992, Diabetes.
[688] G. Pellegrini,et al. Plasminogen Activator Inhibitor Type 1 Is Increased in the Arterial Wall of Type II Diabetic Subjects , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[689] M. Massi-Benedetti,et al. The Costs of Type 2 Diabetes Mellitus in Italy , 2003, Treatments in endocrinology.
[690] S. Gottlieb,et al. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. , 1998, The New England journal of medicine.
[691] J. Tuomilehto,et al. The validity of the Finnish Diabetes Risk Score for the prediction of the incidence of coronary heart disease and stroke, and total mortality , 2005, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[692] J. Gardin,et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). , 1994, The American journal of cardiology.
[693] O. Ljungqvist,et al. Insulin resistance: a marker of surgical stress. , 1999, Current opinion in clinical nutrition and metabolic care.
[694] S. Kaplan,et al. Longitudinal assessment of quality of life in patients with type 2 diabetes and self-reported erectile dysfunction. , 2005, Diabetes care.
[695] S. Haffner,et al. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. , 2002, Diabetes care.
[696] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[697] H. Diener,et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): Randomized, double-blind, placebo-controlled trial , 2004 .
[698] Jaakko Tuomilehto,et al. The diabetes risk score: a practical tool to predict type 2 diabetes risk. , 2003, Diabetes care.
[699] Bruce H. R. Wolffenbuttel,et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.
[700] B. Rodrigues,et al. Metabolic disturbances in diabetic cardiomyopathy , 1998, Molecular and Cellular Biochemistry.
[701] R. Pratley,et al. The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus , 2001, Diabetologia.
[702] Farris K. Timimi,et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. , 1998, Circulation.
[703] K. Channon,et al. Mechanisms of Increased Vascular Superoxide Production in Human Diabetes Mellitus: Role of NAD(P)H Oxidase and Endothelial Nitric Oxide Synthase , 2002, Circulation.
[704] Samuel Wann,et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committ , 2006, European heart journal.
[705] Teven,et al. MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .
[706] W. Kannel,et al. Role of diabetes in congestive heart failure: the Framingham study. , 1974, The American journal of cardiology.
[707] B. Jönsson,et al. Diabetes: the cost of illness in Sweden , 1998, Journal of internal medicine.
[708] P. Vokonas,et al. A comparison of the Framingham and European Society of Cardiology coronary heart disease risk prediction models in the normative aging study. , 2002, American heart journal.
[709] S. Yusuf,et al. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. , 2002, Diabetes care.
[710] B. Lunenfeld. Infertility throughout the ages. , 1995, Studies in profertility series.
[711] H. Adams,et al. Prevalence of diabetes mellitus among patients with subarachnoid hemorrhage. , 1984, Archives of neurology.
[712] D. Brater,et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure , 1995, Clinical pharmacology and therapeutics.
[713] X. Jouven,et al. Diabetes as a risk factor for sudden death , 1999, The Lancet.
[714] Jukka T Salonen,et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.
[715] Paul M. Vanhoutte,et al. The Endothelium: Modulator of Cardiovascular Function , 1990 .
[716] X. Álvarez,et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events , 2007 .
[717] J. Colwell. Aspirin Therapy in Diabetes , 1997, Diabetes Care.
[718] K. Swedberg,et al. [Expert Consensus document on beta-adrenergic receptor blockers]. , 2004, Revista espanola de cardiologia.
[719] W. Rand,et al. Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy. , 2000, American heart journal.
[720] Catherine Sudlow,et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.
[721] R. Hall,et al. The Coronary Artery Revascularisation in Diabetes (CARDia) trial: background, aims, and design. , 2005, American heart journal.
[722] J. Ottervanger,et al. Primary angioplasty compared with thrombolysis in acute myocardial infarction in diabetic patients. , 1999, Diabetes care.
[723] C. Loria,et al. Subclinical states of glucose intolerance and risk of death in the U.S. , 2001, Diabetes care.
[724] E. Barrett-Connor,et al. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. , 1991, JAMA.
[725] Seppo Lehto,et al. Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. , 2005, Diabetes care.
[726] M. Hanefeld,et al. Postprandial glucose regulation and diabetic complications. , 2004, Archives of internal medicine.
[727] J. Tuomilehto,et al. Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome , 2005, Diabetes & vascular disease research.
[728] M. Laakso,et al. Epidemiological evidence for the association of hyperglycaemia and atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. , 1996, Annals of medicine.
[729] E. Antman,et al. Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy. , 2002, American heart journal.
[730] L. Niskanen,et al. Autonomic neuropathy predicts the development of stroke in patients with non-insulin-dependent diabetes mellitus. , 1996, Stroke.
[731] C. van Weel,et al. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. , 2005, Diabetes care.
[732] Shankuan Zhu,et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. , 2003, Archives of internal medicine.
[733] K. Swedberg,et al. Expert consensus document on beta-adrenergic receptor blockers. , 2004, European heart journal.
[734] R. Heethaar,et al. Glucose tolerance and other determinants of cardiovascular autonomic function: the Hoorn Study , 2000, Diabetologia.
[735] P. Poole‐Wilson,et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.
[736] C. Chiu,et al. Salmonella typhimurium brain abscess in a six-month-old infant: a case report and review of the literature. , 1997, Changgeng yi xue za zhi.
[737] S. Mudaliar,et al. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. , 2003, Diabetes care.
[738] P A Wolf,et al. Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. , 2001, Circulation.
[739] F. Vancheri,et al. Impaired glucose metabolism in patients with acute stroke and no previous diagnosis of diabetes mellitus. , 2005, QJM : monthly journal of the Association of Physicians.
[740] G. V. Berghe,et al. Intensive insulin therapy in critically ill patients. , 2001, The New England journal of medicine.
[741] P. Savage,et al. Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria , 1999, The Lancet.
[742] Scott K Aberegg,et al. Intensive insulin therapy in the medical ICU. , 2006, The New England journal of medicine.
[743] H. King,et al. Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections , 1998, Diabetes Care.
[744] Y Li,et al. Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus. , 2001, American journal of physiology. Heart and circulatory physiology.
[745] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.
[746] Ameet Bakhai,et al. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial , 2002, The Lancet.
[747] J. Herman,et al. Diabetes and hypertension. Blood pressure in clinical diabetic patients and a control population. , 1989, Archives of internal medicine.
[748] L Heinemann,et al. Prevalence of renal artery stenosis in diabetes mellitus — an autopsy study , 1991, Journal of internal medicine.
[749] Shah Ebrahim,et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2004, European heart journal.
[750] S. Haffner,et al. Are risk factors for conversion to NIDDM similar in high and low risk populations? , 1997, Diabetologia.
[751] K. Feingold,et al. Infection and inflammation-induced proatherogenic changes of lipoproteins. , 2000, The Journal of infectious diseases.
[752] Deepak L. Bhatt,et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. , 2002, The American journal of cardiology.